The continuing challenge of metallo-β-lactamase inhibition: mechanism matters

LC Ju, Z Cheng, W Fast, RA Bonomo… - Trends in …, 2018 - cell.com
Metallo-β-lactamases (MBLs) are a significant clinical problem because they hydrolyze and
inactivate nearly all β-lactam-containing antibiotics. These 'lifesaving drugs' constitute> 50 …
被引用次数：138 相关文章

The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters.

LC Ju, Z Cheng, W Fast, RA Bonomo… - Trends in …, 2018 - europepmc.org
Abstract Metallo-β-lactamases (MBLs) are a significant clinical problem because they
hydrolyze and inactivate nearly all β-lactam containing antibiotics. These “lifesaving drugs” …

The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

LC Ju, Z Cheng, W Fast, RA Bonomo… - Trends in …, 2018 - Elsevier
HighlightsClinical resistance to β-lactam-containing antibiotics due to bacterial expression of
metallo-β-lactamases (MBLs) is becoming more prevalent and problematic.MBL inhibitors …

The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

LC Ju, Z Cheng, W Fast… - Trends in …, 2018 - pubmed.ncbi.nlm.nih.gov
Metallo-β-lactamases (MBLs) are a significant clinical problem because they hydrolyze and
inactivate nearly all β-lactam-containing antibiotics. These'lifesaving drugs' constitute> 50 …
[HTML] nih.gov

[HTML][HTML] The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

LC Ju, Z Cheng, W Fast, RA Bonomo… - Trends in …, 2018 - ncbi.nlm.nih.gov
Abstract Metallo-β-lactamases (MBLs) are a significant clinical problem because they
hydrolyze and inactivate nearly all β-lactam containing antibiotics. These “lifesaving drugs” …

[引用][C] The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters

LC Ju, Z Cheng, W Fast, RA Bonomo… - Trends in …, 2018 - cir.nii.ac.jp
The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …